Связь рутинных параметров анализа крови с риском фибрилляции предсердий у больных с острым коронарным синдромом по данным регистра Краснодарского края
Кардиология
Дата публикации: ноября 26, 2018
Ключевые слова
острый коронарный синдром
регистр
фибрилляция предсердий
эритроциты
гемоглобин
гематокрит
регистр
фибрилляция предсердий
эритроциты
гемоглобин
гематокрит
Как цитировать
Татаринцева З. Г., Космачева Е. Д., Кручинова С. В. Связь рутинных параметров анализа крови с риском фибрилляции предсердий у больных с острым коронарным синдромом по данным регистра Краснодарского края // Кремлевская медицина. Клинический вестник. 2018. Т. 1. № 4. С. 21-24.
Аннотация
Фибрилляция предсердий (ФП) является распространенным осложнением острого коронарного синдрома (ОКС) и связана с увеличением заболеваемости и смертности. Целью данного ретроспективного исследования явилось изучение связи различных параметров крови с развитием нового случая ФП на фоне ОКС. При сравнительном анализе показателей крови в группе пациентов с сочетанием ОКС и нового эпизода ФП и пациентов с ОКС и сохранным синусовым ритмом наблюдались достоверно (р<0,05) более высокие уровни гемоглобина, гематокрита и эритроцитов у пациентов из группы ОКС и ФП. В противовес вышесказанному по уровню лейкоцитов и тромбоцитов в крови не обнаружено существенных различий (р>0,05).Данное исследование демонстрирует независимую связь между сывороточным гемоглобином, гематокритом, количеством эритроцитов и возникновением фибрилляции предсердий на фоне ОКС.Литература
1. Schmitt J., Duray G., Gersh B.J. et al. Atrial fibrillation with acute myocardial infarction: a systematic review of morbidity, clinical features and prognostic consequences. Eur. Heart J. 2009; 30: 1038–1045. DOI:10,1093/eurheartj/ehn579.
2. Jabre P., Jouven X., Adnet F. et al. Atrial fibrillation and death after myocardial infarction: community study. The circulation of. 2011; 123:2094–2100. DOI:10,1161/CIRCULATIONAHA.110.990192.
3. Jabre P., Roger V.L., Murad M.H. et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. The circulation of. 2011; 123: 1587-1593. DOI:10,1161/CIRCULATIONAHA.110.986661.
4. Zusman O., Amit G., Gilutz H. et al. The significance of the newatrial fibrillation complicating acute myocardial infarction. Clin. Res. Cardiol.2012; 101: 17-22. DOI:10,1007/s00392-011-0357-5.
5. Angiolillo D.J., Goodman S.G., Bhatt D.L. et al. Antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary intervention: North American perspective-2016. Circ. Cardiovasc.Interv. 2016; 9: 9. doi: 10.1161 / CIRCINTERVENTIONS.116.004395.
6. Konstantino Y., Zelnik Y.D., Friger M.D. et al. Postoperative Atrial Fibrillation Following Coronary Artery Bypass Graft Surgery Predicts Long-Term Atrial Fibrillation and Stroke. Isr. Med. Assoc. J. 2016; 18:744–748.
7. Gibson P.H., Cuthbertson B.H., Croal B.L. et al. Utility of neutrophil/ lymphocyte ratio as a predictor of atrial atrial fibrillation after coronary artery bypass. Am. J. Cardiol. 2010; 105: 186–191. DOI:10,1016/j.amjcard.2009.09.007.
8. Soliman E.Z. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015; 131:1843–1850. doi: 10.1161/CIRCULATIONAHA.114.014145.
9. Rienstra M., Sun J.X., Magnani J.W. et al. The number of white blood cells and the risk of atrial fibrillation (from the study of the heart of Framingham). Am. J. Cardiol. 2012; 109: 533–537.
10. Fuster V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 guidelines for the management of patient with atrial fibrillation - executive summary: a report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation).J. Am. Coll. Cardiol. 2006; 48-854. DOI:10,1016/j.jacc.2006.07.009.
11. Hijazi Z., Oldgren J., Sigbana et al. The use of biomarkers for risk stratification in patients with atrial fibrillation. Clin. Chem. 2017; 63–152-164. DOI:10,1373 / clinchem.2016.255182.
12. Hijazi Z., Wallentin L., Sigbana et al. N-terminal natriuretic peptide pro-B-type for risk assessment in patients with atrial fibrillation. J. Am.Coll. Cardiol. 2013; 61–2274-2284. DOI:10,1016 / j.jacc.2012.11.082.
13. Wallentin L., Hijazi Z., Andersson U. et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: an insight from Apixaban to reduce stroke and other thromboembolic events in the study of atrial fibrillation(ARISTOTLE). Circulation. 2014; 130–1847-1858. DOI:10,1161 /CIRCULATIONAHA.114.011204.
14. Pastori D. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. Int. J. Cardiol. 2015; 201: 513–516. doi: 10.1016/j.ijcard.2015.08.054.15. Bishara R., Telman G., Bahut F. et al. Precision atrial fibrillation and risk of stroke after acute myocardial infarction. Thromb. Haemost.2011; 106: 877–84. DOI:10,1160 / TH11-05-0343.
2. Jabre P., Jouven X., Adnet F. et al. Atrial fibrillation and death after myocardial infarction: community study. The circulation of. 2011; 123:2094–2100. DOI:10,1161/CIRCULATIONAHA.110.990192.
3. Jabre P., Roger V.L., Murad M.H. et al. Mortality associated with atrial fibrillation in patients with myocardial infarction: a systematic review and meta-analysis. The circulation of. 2011; 123: 1587-1593. DOI:10,1161/CIRCULATIONAHA.110.986661.
4. Zusman O., Amit G., Gilutz H. et al. The significance of the newatrial fibrillation complicating acute myocardial infarction. Clin. Res. Cardiol.2012; 101: 17-22. DOI:10,1007/s00392-011-0357-5.
5. Angiolillo D.J., Goodman S.G., Bhatt D.L. et al. Antithrombotic therapy in patients with atrial fibrillation who underwent percutaneous coronary intervention: North American perspective-2016. Circ. Cardiovasc.Interv. 2016; 9: 9. doi: 10.1161 / CIRCINTERVENTIONS.116.004395.
6. Konstantino Y., Zelnik Y.D., Friger M.D. et al. Postoperative Atrial Fibrillation Following Coronary Artery Bypass Graft Surgery Predicts Long-Term Atrial Fibrillation and Stroke. Isr. Med. Assoc. J. 2016; 18:744–748.
7. Gibson P.H., Cuthbertson B.H., Croal B.L. et al. Utility of neutrophil/ lymphocyte ratio as a predictor of atrial atrial fibrillation after coronary artery bypass. Am. J. Cardiol. 2010; 105: 186–191. DOI:10,1016/j.amjcard.2009.09.007.
8. Soliman E.Z. Atrial Fibrillation and Risk of ST-Segment-Elevation Versus Non-ST-Segment-Elevation Myocardial Infarction: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation. 2015; 131:1843–1850. doi: 10.1161/CIRCULATIONAHA.114.014145.
9. Rienstra M., Sun J.X., Magnani J.W. et al. The number of white blood cells and the risk of atrial fibrillation (from the study of the heart of Framingham). Am. J. Cardiol. 2012; 109: 533–537.
10. Fuster V., Ryden L.E., Cannom D.S. et al. ACC/AHA/ESC 2006 guidelines for the management of patient with atrial fibrillation - executive summary: a report of the American College of Cardiology. American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (writing committee to revise the 2001 guidelines for the management of patients with atrial fibrillation).J. Am. Coll. Cardiol. 2006; 48-854. DOI:10,1016/j.jacc.2006.07.009.
11. Hijazi Z., Oldgren J., Sigbana et al. The use of biomarkers for risk stratification in patients with atrial fibrillation. Clin. Chem. 2017; 63–152-164. DOI:10,1373 / clinchem.2016.255182.
12. Hijazi Z., Wallentin L., Sigbana et al. N-terminal natriuretic peptide pro-B-type for risk assessment in patients with atrial fibrillation. J. Am.Coll. Cardiol. 2013; 61–2274-2284. DOI:10,1016 / j.jacc.2012.11.082.
13. Wallentin L., Hijazi Z., Andersson U. et al. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: an insight from Apixaban to reduce stroke and other thromboembolic events in the study of atrial fibrillation(ARISTOTLE). Circulation. 2014; 130–1847-1858. DOI:10,1161 /CIRCULATIONAHA.114.011204.
14. Pastori D. Inadequate anticoagulation by Vitamin K Antagonists is associated with Major Adverse Cardiovascular Events in patients with atrial fibrillation. Int. J. Cardiol. 2015; 201: 513–516. doi: 10.1016/j.ijcard.2015.08.054.15. Bishara R., Telman G., Bahut F. et al. Precision atrial fibrillation and risk of stroke after acute myocardial infarction. Thromb. Haemost.2011; 106: 877–84. DOI:10,1160 / TH11-05-0343.